Desmoid tumor
Drug research and approvals for desmoid tumor: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 19 studies of desmoid tumor are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- A Study in Adults With Desmoid TumorsNCT07541430 · Phase 2 · Elpiscience (Suzhou) Biopharma, Ltd. · starts Apr 24, 2026
- Immunological Phenotype of Desmoid-fibromatosis-affected Patients.NCT07496242 · Not reported · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · starts May 27, 2025
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)NCT07176689 · Phase 4 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · starts Sep 17, 2025
- Treatment of Desmoid Fibromatosis With Arterial EmbolizationNCT06945887 · Not reported · Istituto Ortopedico Rizzoli · starts Jul 1, 2025
- Arterial Chemoembolization for the Treatment of Desmoid FibromatosisNCT06268457 · Not reported · Istituto Ortopedico Rizzoli · starts Feb 20, 2024
- Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After CryoablationNCT06224283 · Not reported · Istituto Ortopedico Rizzoli · starts Feb 20, 2024
- Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful WaitingNCT06081400 · Not applicable · University Hospital, Strasbourg, France · starts Mar 4, 2024
- Study of Cryoablation and Nirogacestat for Desmoid TumorNCT05949099 · Phase 2 · Nam Bui · starts Aug 15, 2023
- FOG-001 in Locally Advanced or Metastatic Solid TumorsNCT05919264 · Phase 1 / Phase 2 · Parabilis Medicines, Inc. · starts May 23, 2023
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 27, 2023 | OgsiveoFor adult patients with progressing desmoid tumors who require systemic treatment | SpringWorks Therapeutics, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA